Gilead Sciences, Inc. prepared investors to be underwhelmed by the Phase III data results from TROPICS-02, testing Trodelvy (sacituzumab govitecan-hziy) versus chemotherapy in heavily pre-treated HR-positive/HER2-negative metastatic breast cancer. So the data – presented at the American Society of Clinical Oncology (ASCO) annual meeting on 4 June – were about what investors were expecting or slightly better.
Nonetheless, impressive Phase III data at ASCO for a different antibody drug conjugate (ADC), AstraZeneca PLC/Daiichi Sankyo Co.,...



![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

